ZURICH (Reuters) - Swiss pharmaceutical company Novartis AG said it has mapped the genome of a large group of type-2 diabetes patients, enabling scientists to better search for the genes causing the disease.>>> Discuss This Story
ZURICH (Reuters) - Swiss pharmaceutical company Novartis AG said it has mapped the genome of a large group of type-2 diabetes patients, enabling scientists to better search for the genes causing the disease.>>> Discuss This Story